IMCR - Multiplikator P/S Immunocore PLC

Tandha merek Immunocore Corp (IMCR)

The volatility demonstrated by the price-to-sales ratio underscores the status of Immunocore Holdings plc (IMCR) as an authoritative center for immuno-oncology. Stability is provided by revolutionary treatments for ocular melanoma and a robust patent shield that shuts out competitors. The value of 3.50 captures the current state of the parameter, helping to assess the market value of the company's sales against the backdrop of strict FDA requirements and costly research.

IMCR (Immunocore PLC) riwayat Rasio rega marang pendapatan saka 04.07.2022 nganti 17.11.2026

Immunocore PLC (IMCR) - rincian metrik lan laporan keuangan

- rega pasar lan target rega analis:
Analisis umum perusahaan:Immunocore, IMCR
Produk asil prodhuksi Immunocore Holdings

The P/S multiple relates market capitalization to annual sales volume, allowing for a business valuation that excludes net income volatility. The current value of 3.50 in the revenue multiple trend reflects market expectations for the commercialization of the melanoma drug, where the growth of actual sales proceeds is gradually transforming the speculative valuation of Immunocore Holdings plc (IMCR) into fundamental stability and self-sufficiency.

Perusahaan pesaing

Kapitalisasi marang pendapatan ImmunityBio Corp IBRX|Janux Therapeutics Inc - Kapitalisasi marang pendapatan|Multiplikator P/S Arcus Corp RCUS|ZYME - Rasio rega marang pendapatan|TNGX (tangotx.com) - Rasio kapitalisasi marang pendapatan|Iovance Corp (IOVA) - Rasio rega marang pendapatan|Rega marang dodolan Immatics Corp (IMTX)|Kapitalisasi marang pendapatan XNCR|CMPX - Multiplikator rega marang pendapatan|Kapitalisasi marang pendapatan REPL (Replimune Corp)|Kapitalisasi marang volume dodolan LYEL|Multiplikator P/S IPHA (Innate Pharma)|Rasio kapitalisasi pasar marang pendapatan PYXS|Compugen Limited - Multiplikator P/S|Rega marang dodolan IO Biotech Inc.|Sutro Biopharma, Inc. (STRO) - Rasio rega marang pendapatan|MiNK Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|HOWL (Werewolf) - Multiplikator P/S|Multiplikator P/S immixbio.com|Rasio rega marang pendapatan ALX Oncology Holdings (ALXO)|CUE - Rega marang dodolan|PDS Biotechnology Corporation - Kapitalisasi marang pendapatan|Sonnet BioTherapeutics (SONN) - Rega marang dodolan|MAIA - Rasio rega marang pendapatan|LIMN: Rasio rega marang pendapatan|LVTX: Multiplikator P/S|Rega marang dodolan NextCure, Inc. (NXTC)|LPTX (Leap Tx) - Multiplikator P/S|INTS (Intensity Therapeutics) - Kapitalisasi marang volume dodolan|Rasio rega marang pendapatan Sensei Bio (SNSE)|TOVX (Theriva Biologics) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan gritstonebio.com GRTS|Rasio kapitalisasi pasar marang pendapatan KA|NEXI - Rasio rega marang pendapatan|Turnstone Biologics Corp. - Kapitalisasi marang volume dodolan|VCNX: Multiplikator P/S|Rasio kapitalisasi marang pendapatan HARP